Dario Expands Provider-Backed Cardiometabolic Platform with New Women's Health and Sleep Solutions Aligning with Client Demand

Rhea-AI Summary

DarioHealth (NASDAQ: DRIO) announced the launch of two new provider-backed programs, Dario Women™ and Dario Sleep™, expanding its AI-enabled cardiometabolic platform into women's health and sleep. The programs integrate AI-powered engagement, human behavioral coaching and licensed healthcare providers to address perimenopause/menopause-related cardiometabolic risks and obstructive sleep apnea (OSA).

According to DarioHealth, both solutions are expected to roll out to Fortune 500 and other clients in Fall 2026, with recurring digital platform revenue per engaged member per month anticipated to begin in Q4 2026 and provider-backed care revenue expected from late 2026 into early 2027. The company aims to increase revenue opportunities with existing enterprise customers by offering additional high-cost clinical categories on the same integrated platform, which already covers diabetes, hypertension, weight management, musculoskeletal, behavioral health, women's health and sleep.

Positive

• Dario Women™ and Dario Sleep™ launched expanding cardiometabolic platform into two new clinical areas
• Enterprise rollout targeted for Fall 2026 to Fortune 500 and other clients
• New recurring revenue streams expected starting Q4 2026 from digital platform engagement
• Provider-backed care revenue anticipated from late 2026 into early 2027
• Broader participation in reimbursement-driven services via integrated provider-backed care model across conditions

Negative

• None.

Market Context

Recent historical reactions ranged from -7.2% to 12.86% across Dario announcements, providing a mixe...

Analysis

Recent historical reactions ranged from -7.2% to 12.86% across Dario announcements, providing a mixed-response baseline for this launch. Low short positioning adds limited positioning context, while the confirmed S-3 shelf remains a financing risk.

Key Figures

Client rollout: Fall 2026 Digital platform revenue: Q4 2026 Provider-backed care revenue: End of 2026 to beginning of 2027 +5 more

8 metrics

Client rollout Fall 2026 Dario Women and Dario Sleep

Digital platform revenue Q4 2026 Recurring revenue contribution per engaged member expected to commence

Provider-backed care revenue End of 2026 to beginning of 2027 Anticipated contribution from provider-backed care services

Metabolic syndrome incidence One in three women During menopause transition

OSA healthcare cost multiple 2.5× higher Annual healthcare costs for untreated OSA patients versus individuals without OSA

OSA medical cost increase Approximately 50% Higher annual medical costs for cardiometabolic patients with OSA

Average annual cost increase More than $6,185 per member per year Cardiometabolic patients with OSA

Proprietary healthcare data More than 13 billion data points Collected over more than a decade

Historical Context

5 past events · Latest: Jul 22 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 22	Registered direct offering	Negative	+12.9%	Registered direct offering priced at $6.80 per share for gross proceeds.
Jul 16	Fortune 50 contract	Positive	+0.3%	Fortune 50 employer contract covered more than 100,000 eligible employees launching in Fall 2026.
Jul 13	AI platform expansion	Positive	-7.2%	DarioIQ deployment projected 10%–15% annual recurring-revenue increase from existing customers.
Jul 06	Insurer partnership	Positive	-1.5%	Arizona insurer agreement expanded access through Amwell to hundreds of thousands of covered lives.
Jul 02	Health plan expansion	Positive	+7.8%	National health plan expanded into cardiometabolic care, potentially tripling the client revenue opportunity.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Dario's recent announcements produced mixed reactions, with two aligned outcomes and three divergences.

Key Terms

cardiometabolic, hormone replacement therapy (hrt), obstructive sleep apnea (osa), cpap therapy, +1 more

5 terms

cardiometabolic medical

"The two new programs address important drivers of cardiometabolic health"

Cardiometabolic describes health conditions that affect the heart and the body’s metabolism—most commonly heart disease, high blood pressure, type 2 diabetes and obesity—that often occur together and share common causes. Investors care because these linked conditions drive large, predictable demand for drugs, medical devices and long-term care, and changes in treatment options, guidelines or costs can materially affect healthcare company revenues and government spending much like a problem in an engine and its fuel system impacts the whole vehicle.

hormone replacement therapy (hrt) medical

"Eligible members may receive clinical evaluation for hormone replacement therapy (HRT)"

A medical treatment that replaces or supplements hormones the body no longer makes in sufficient amounts, such as estrogen, progesterone, or testosterone; it can be given as pills, patches, gels, injections, or implants. Investors watch HRT because demand, safety findings, regulatory approvals, patent status and clinical study results can directly affect sales, market size and the valuation of companies that develop, manufacture or sell these therapies—think of it like tracking product supply and safety for a widely used health supplement.

obstructive sleep apnea (osa) medical

"Dario Sleep addresses obstructive sleep apnea (OSA)"

A sleep disorder where a person repeatedly stops breathing or breathes very shallowly during sleep because the airway partly or fully closes, causing snoring, daytime tiredness, and other health risks. Investors care because it drives demand for medical devices, diagnostics, treatments, and ongoing healthcare costs—similar to a chronic equipment failure in a factory that reduces output and increases maintenance and regulatory oversight, affecting revenue, reimbursement and long‑term market growth.

cpap therapy medical

"treatment pathways, which may include positional therapy, oral appliance therapy, CPAP therapy"

CPAP therapy is a medical treatment that delivers a steady flow of air through a mask while a person sleeps to keep the airway open and prevent pauses in breathing, commonly used for sleep apnea. Investors care because CPAP devices, masks and replaceable parts create a recurring-product market influenced by patient adherence, clinical effectiveness, insurance reimbursement and regulatory approvals, all of which affect sales, service revenue and long-term growth.

glp-1 treatment medical

"oral appliance therapy, CPAP therapy or GLP-1 treatment when clinically appropriate"

GLP-1 treatment refers to medicines that mimic the gut hormone glucagon-like peptide-1 (GLP-1) to activate receptors that help the body release insulin, lower blood sugar, slow stomach emptying, and reduce appetite. Think of them as a thermostat that helps regulate both blood sugar and hunger; they matter to investors because their clinical benefits, regulatory approvals, prescription volume, and pricing can drive significant revenue, influence healthcare spending, and affect related companies across drugs, devices, and insurers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

New programs, expected to begin revenue contribution Q4 2026, extend Dario's integrated healthcare platform into two high-impact clinical categories while advancing execution of the Company's provider-backed care strategy

AI-enabled programs combine digital engagement, human behavioral coaching and clinical care to improve outcomes while expanding Dario's participation in reimbursement-driven healthcare services

NEW YORK, Aug. 4, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced it has further expanded its provider-backed cardiometabolic platform with the launch of Dario Women™ and Dario Sleep™. The two new programs address important drivers of cardiometabolic health through an integrated care experience combining AI-powered engagement, behavioral support and access to licensed healthcare providers.

The new offerings come as demand from large enterprise payers for multi-condition solutions continues to rise, and single point offerings are phased out. While increasing the indications supported by its platform, Dario has further expanded into provider-backed care to broaden participation in reimbursement-driven healthcare services.

Both Dario Women™ and Dario Sleep™ are expected to roll out to the Company's Fortune 500 and other clients in Fall 2026. Recurring revenue contribution per engaged member per month for the digital health platform is expected to commence in the fourth quarter of 2026, with revenue from the provider-backed care services anticipated at the end of 2026 and into the beginning of 2027. The new programs are expected to expand revenue opportunities across Dario's existing enterprise customer base by allowing employers and health plans to address additional high-cost clinical needs through the same integrated platform.

"Dario continues to execute on our strategy of integrating provider-backed care throughout our expanding chronic condition platform," said Erez Raphael, Chief Executive Officer of Dario. "Women's health and sleep represent significant opportunities to improve cardiometabolic outcomes while expanding the value we deliver to employers, health plans and members. As we continue adding clinical capabilities to our platform, we strengthen our ability to support members throughout their healthcare journey while creating new opportunities to grow revenue through healthcare services that extend beyond digital engagement." 

Dario Women: Supporting Women's Cardiometabolic Health

Dario Women, developed in-house and native to Dario's solution, supports members navigating perimenopause and menopause, life stages frequently associated with weight changes, sleep disruption, metabolic changes and increased cardiometabolic risk, with one in three women developing metabolic syndrome during menopause transition¹.

The program combines AI-powered engagement, personalized human-led behavioral coaching and access to licensed healthcare providers in one, connected member experience. Eligible members may receive clinical evaluation for hormone replacement therapy (HRT), when medically appropriate, following a comprehensive clinical assessment conducted in accordance with evidence-based clinical guidelines and applicable regulations.

Dario Sleep: Connecting Sleep Health to Cardiometabolic Care

Dario Sleep addresses obstructive sleep apnea (OSA), a significant contributor to cardiometabolic disease and rising healthcare costs.

Published research has shown that untreated OSA patients incur approximately 2.5× higher annual healthcare costs than individuals without OSA.² Cardiometabolic patients with OSA also generate approximately 50% higher annual medical costs, representing an average increase of more than $6,185 per member per year.³

The Dario Sleep program enables eligible members to complete a one-night, clinical-grade home sleep test with real-time data transmitted directly to licensed healthcare providers for evaluation. Based on individual clinical needs, providers determine appropriate treatment pathways, which may include positional therapy, oral appliance therapy, CPAP therapy or GLP-1 treatment when clinically appropriate.

"Our goal is to connect members with the right care through one coordinated experience," said Lara Dodo, Chief Operating Officer of Dario. "By integrating AI-powered engagement, behavioral coaching and provider-backed clinical care within one platform, we help members access appropriate treatment while giving employers and health plans a more comprehensive solution for managing interconnected chronic conditions."

Members enrolled in Dario Women and Dario Sleep continue their care journey through Dario's integrated healthcare platform, which combines connected devices, AI-powered insights, personalized coaching and provider-backed clinical care across diabetes, hypertension, weight management, ergonomic posture, behavioral health, women's health and sleep.

¹ Janssen I, Powell LH, Crawford S, Lasley B, Sutton-Tyrrell K. Menopause and the metabolic syndrome: the Study of Women's Health Across the Nation. Arch Intern Med. 2008;168(14):1568-1575. doi:10.1001/archinte.168.14.1568. PMID: 18663170. https://pubmed.ncbi.nlm.nih.gov/18663170/

² Zappala P, et al. The Global Socioeconomic Burden of Obstructive Sleep Apnea: A Comprehensive Review. Healthcare (Basel). 2025;13(17):2115. https://doi.org/10.3390/healthcare13172115

³ Patel U. Sleep apnea drives average medical costs up 50% for patients with cardio/obesity. Evernorth Research Institute, January 26, 2024. https://www.evernorth.com/articles/sleep-apnea-cardiodiabesity-medical-costs 

About DarioHealth Corp. (Nasdaq: DRIO)

DarioHealth (Nasdaq: DRIO) is an AI-powered healthcare technology company helping health plans, health systems and employers improve health outcomes while lowering the cost of care. The Company's integrated platform combines connected devices, personalized member engagement, AI-driven insights and provider-backed clinical care to support people living with conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health needs.

Powered by more than 13 billion proprietary longitudinal healthcare data points collected over more than a decade, Dario's AI platform personalizes care at the individual member level by analyzing biometric, clinical and behavioral data to deliver more timely and effective interventions. By combining engagement, clinical intelligence and care delivery within a single platform, Dario helps customers address multiple chronic conditions through one solution.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the expected launch and implementation of the programs; the timing of anticipated revenue contribution by the programs; that the new programs are expected to expand revenue opportunities across Dario's existing enterprise customer base; and the benefits and uses of the Company's platform and programs. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contacts

Michael Lipari
SVP Corporate Development
irteam@dariohealth.com
+1-201-785-6310

Rob Halpern
SVP Marketing
irteam@dariohealth.com 

Logo - https://mma.prnewswire.com/media/2866807/6030938/Dario_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/dario-expands-provider-backed-cardiometabolic-platform-with-new-womens-health-and-sleep-solutions-aligning-with-client-demand-302841434.html

SOURCE DarioHealth Corp.

FAQ

What new programs did DarioHealth (NASDAQ: DRIO) launch in August 2026?

DarioHealth launched Dario Women™ and Dario Sleep™, expanding its provider-backed cardiometabolic platform. According to DarioHealth, these AI-enabled programs combine digital engagement, human behavioral coaching and licensed healthcare providers to address women’s perimenopause/menopause cardiometabolic risks and obstructive sleep apnea within one integrated care experience.

When will Dario Women and Dario Sleep start generating revenue for DRIO?

According to DarioHealth, recurring digital-platform revenue per engaged member per month is expected to begin in Q4 2026. Revenue from provider-backed care services tied to these programs is anticipated at the end of 2026 and into the beginning of 2027, subject to rollout and adoption.

How do Dario Women and Dario Sleep fit into DarioHealth’s provider-backed care strategy (DRIO)?

The programs extend DarioHealth’s provider-backed cardiometabolic platform by adding women’s health and sleep under one integrated system. According to DarioHealth, this approach broadens participation in reimbursement-driven healthcare services while giving employers and health plans multi-condition management through a single coordinated experience.

What clinical needs do Dario Women and Dario Sleep address for DarioHealth (DRIO) clients?

Dario Women targets perimenopause and menopause, linked to weight, sleep and metabolic changes. Dario Sleep focuses on obstructive sleep apnea. According to DarioHealth, both programs connect members to AI-enabled engagement, behavioral coaching and clinical evaluation, including HRT assessment and home sleep testing when appropriate.

Which customers are expected to adopt DarioHealth’s new women’s health and sleep solutions?

According to DarioHealth, Dario Women and Dario Sleep are expected to roll out to the company’s Fortune 500 and other enterprise clients beginning in Fall 2026. The offerings aim to help employers and health plans manage additional high-cost cardiometabolic-related conditions on Dario’s existing integrated platform.